CoChat
Sign Up
Cited by 41CAR-T cell therapy researchImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

Rapid transduction and expansion of transduced T cells with maintenance of central memory populations

Open access
Pampusch, Mary S., Haran, Kumudhini Preethi, Hart, Geoffrey T., Rakasz, Eva G., Rendahl, Aaron K., Berger, Edward A., Connick, Elizabeth, Skinner, Pamela J.·2020·Molecular Therapy - Methods & Clinical Development
DOI 10.1016/j.omtm.2019.09.007PMC PMC6816036
Open this paper in CoChat — free accountOpen PDF

Abstract

Chimeric antigen receptor (CAR)-T cells show great promise in treating cancers and viral infections. However, most protocols developed to expand T cells require relatively long periods of time in culture, potentially leading to progression toward populations of terminally differentiated effector memory cells. Here, we describe in detail a 9-day protocol for CAR gene transduction and expansion of primary rhesus macaque peripheral blood mononuclear cells (PBMCs). Cells produced and expanded with this method show high levels of viability, high levels of co-expression of two transduced genes, retention of the central memory phenotype, and sufficient quantity for immunotherapeutic infusion of 1–2 × 10 8 cells/kg in a 10 kg rhesus macaque. This 9-day protocol may be broadly used for CAR-T cell and other T cell immunotherapy approaches to decrease culture time and increase maintenance of central memory populations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtm.2019.09.007

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In 2011, the FDA published a study that acknowledged rapid sterility tests as an alternative.

    “In 2011, the FDA published a study that acknowledged rapid sterility tests as an alternative (122).”

    From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [122]

    The Materials and Procedure passages describe T-cell transduction and expansion, not sterility-testing policy. Searches for rapid sterility tests and FDA guidance found no passage in our copy addressing a 2011 FDA study or its acceptance of such tests as an alternative. (LLM, conf=0.75)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 32

  1. [1]Klebanoff C.A. Rosenberg S.A. Restifo N.P. Prospects for gene-engineered T cell immunotherapy for solid cancers Nat. Med. 22 2016 26 36 26735408 PMC6295670
  2. [2]Lim W.A. June C.H. The Principles of Engineering Immune Cells to Treat Cancer Cell 168 2017 724 740 28187291 PMC5553442
  3. [3]Sadelain M. Rivière I. Riddell S. Therapeutic T cell engineering Nature 545 2017 423 431 28541315 PMC5632949
  4. [4]Kuhlmann A. Peterson C.W. Kiem H.P. Chimeric antigen receptor T-cell approaches to HIV cure Curr. Opin. HIV AIDS 13 2018 446 453 29878913 PMC6993924
  5. [5]Ghanem M.H. Bolivar-Wagers S. Dey B. Hajduczki A. Vargas-Inchaustegui D.A. Danielson D.T. Bundoc V. Liu L. Berger E.A. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity Cytotherapy 20 2018 407 419 29306566
  6. [6]Haran K.P. Hajduczki A. Pampusch M.S. Mwakalundwa G. Vargas-Inchaustegui D.A. Rakasz E.G. Connick E. Berger E.A. Skinner P.J. Simian immunodeficiency virus (SIV)-specific chimeric antigen receptor-T cells engineered to target B cell follicles and suppress SIV replication Front. Immunol. 9 2018 492 29616024 PMC5869724
  7. [7]Connick E. Mattila T. Folkvord J.M. Schlichtemeier R. Meditz A.L. Ray M.G. McCarter M.D. Mawhinney S. Hage A. White C. Skinner P.J. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue J. Immunol. 178 2007 6975 6983 17513747
  8. [8]Connick E. Folkvord J.M. Lind K.T. Rakasz E.G. Miles B. Wilson N.A. Santiago M.L. Schmitt K. Stephens E.B. Kim H.O. Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL J. Immunol. 193 2014 5613 5625 25362178 PMC4239212
  9. [9]Ayala V.I. Deleage C. Trivett M.T. Jain S. Coren L.V. Breed M.W. Kramer J.A. Thomas J.A. Estes J.D. Lifson J.D. Ott D.E. CXCR5-Dependent Entry of CD8 T Cells into Rhesus Macaque B-Cell Follicles Achieved through T-Cell Engineering J. Virol. 91 2017 e02507 e02516 28298605 PMC5432868
  10. [10]Patel S. Jones R.B. Nixon D.F. Bollard C.M. T-cell therapies for HIV: Preclinical successes and current clinical strategies Cytotherapy 18 2016 931 942 27265874 PMC4935558
  11. [11]Ma Q. Wang Y. Lo A.S.-Y. Gomes E.M. Junghans R.P. Cell density plays a critical role in ex vivo expansion of T cells for adoptive immunotherapy J. Biomed. Biotechnol. 2010 2010 386545 20625484 PMC2896674
  12. [12]Vargas J.E. Chicaybam L. Stein R.T. Tanuri A. Delgado-Cañedo A. Bonamino M.H. Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives J. Transl. Med. 14 2016 288 302 27729044 PMC5059932
  13. [13]Scholler J. Brady T.L. Binder-Scholl G. Hwang W.-T. Plesa G. Hege K.M. Vogel A.N. Kalos M. Riley J.L. Deeks S.G. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells Sci. Transl. Med. 4 2012 132ra53 PMC4368443 22553251
  14. [14]Pan J. Yang J.F. Deng B.P. Zhao X.J. Zhang X. Lin Y.H. Wu Y.N. Deng Z.L. Zhang Y.L. Liu S.H. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients Leukemia 31 2017 2587 2593 28490811
  15. [15]Brentjens R.J. Rivie I. Park J.H. Davila M.L. Wang X. Stefanski J. Taylor C. Yeh R. Bartido S. Borquez-ojeda O. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 18 2011 4817 4828 PMC3208293 21849486
  16. [16]Taraseviciute A. Tkachev V. Ponce R. Turtle C.J. Snyder J.M. Liggitt H.D. Myerson D. Gonzalez-Cuyar L. Baldessari A. English C. Chimeric antigen receptor T cell–mediated neurotoxicity in nonhuman primates Cancer Discov. 8 2018 750 763 29563103 PMC6058704
  17. [17]Bajgain P. Mucharla R. Wilson J. Welch D. Anurathapan U. Liang B. Lu X. Ripple K. Centanni J.M. Hall C. Optimizing the production of suspension cells using the G-Rex “M” series Mol. Ther. Methods Clin. Dev. 1 2014 14015 26015959 PMC4362380
  18. [18]Vera J.F. Brenner L.J. Gerdemann U. Ngo M.C. Sili U. Liu H. Wilson J. Dotti G. Heslop H.E. Leen A.M. Rooney C.M. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex) J. Immunother. 33 2010 305 315 20445351 PMC2946348
  19. [19]Nakazawa Y. Huye L.E. Salsman V.S. Leen A.M. Ahmed N. Rollins L. Dotti G. Gottschalk S.M. Wilson M.H. Rooney C.M. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor Mol. Ther. 19 2011 2133 2143 21772253 PMC3242651
  20. [20]Jin J. Gkitsas N. Fellowes V.S. Ren J. Feldman S.A. Hinrichs C.S. Stroncek D.F. Highfill S.L. Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules J. Transl. Med. 16 2018 13 29368612 PMC5784598
  21. [21]Redeker A. Arens R. Improving adoptive T cell therapy: The particular role of T cell costimulation, cytokines, and post-transfer vaccination Front. Immunol. 7 2016 345 27656185 PMC5011476
  22. [22]Klebanoff C.A. Gattinoni L. Restifo N.P. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J. Immunother. 35 2012 651 660 23090074 PMC3501135
  23. [23]Pitcher C.J. Hagen S.I. Walker J.M. Lum R. Mitchell B.L. Maino V.C. Axthelm M.K. Picker L.J. Development and homeostasis of T cell memory in rhesus macaque J. Immunol. 168 2002 29 43 11751943
  24. [24]Ghassemi S. Nunez-Cruz S. O’Connor R.S. Fraietta J.A. Patel P.R. Scholler J. Barrett D.M. Lundh S.M. Davis M.M. Bedoya F. Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells Cancer Immunol. Res. 6 2018 1100 1109 30030295 PMC8274631
  25. [25]Minang J.T. Trivett M.T. Bolton D.L. Trubey C.M. Estes J.D. Li Y. Smedley J. Pung R. Rosati M. Jalah R. Distribution, persistence, and efficacy of adoptively transferred central and effector memory-derived autologous simian immunodeficiency virus-specific CD8+ T cell clones in rhesus macaques during acute infection J. Immunol. 184 2010 315 326 19949091 PMC2797560
  26. [26]Bolton D.L. Minang J.T. Trivett M.T. Song K. Tuscher J.J. Li Y. Piatak M. Jr. O’Connor D. Lifson J.D. Roederer M. Ohlen C. Trafficking, persistence, and activation state of adoptively transferred allogeneic and autologous Simian Immunodeficiency Virus-specific CD8(+) T cell clones during acute and chronic infection of rhesus macaques J. Immunol. 184 2010 303 314 19949089 PMC2797565
  27. [27]Berger C. Sommermeyer D. Hudecek M. Berger M. Balakrishnan A. Paszkiewicz P.J. Kosasih P.L. Rader C. Riddell S.R. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells Cancer Immunol. Res. 3 2015 206 216 25355068 PMC4324006
  28. [28]Bruno S. Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells Cell Prolif. 25 1992 31 40 1540682
  29. [29]Younan P.M. Peterson C.W. Polacino P. Kowalski J.P. Obenza W. Miller H.W. Milless B.P. Gafken P. DeRosa S.C. Hu S.L. Kiem H.P. Lentivirus-mediated Gene Transfer in Hematopoietic Stem Cells Is Impaired in SHIV-infected, ART-treated Nonhuman Primates Mol. Ther. 23 2015 943 951 25648264 PMC4427875
  30. [30]Bromley S.K. Thomas S.Y. Luster A.D. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics Nat. Immunol. 6 2005 895 901 16116469
  31. [31]Förster R. Mattis A.E. Kremmer E. Wolf E. Brem G. Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen Cell 87 1996 1037 1047 8978608
  32. [32]Legler D.F. Loetscher M. Roos R.S. Clark-Lewis I. Baggiolini M. Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5 J. Exp. Med. 187 1998 655 660 9463416 PMC2212150

Cited by

Sorted by citations

Authors
Pampusch, M. S., Haran, K. P., Hart, G. T., Rakasz, E. G., Rendahl, A. K., Berger, E. A., Connick, E., & Skinner, P. J.
Affiliations
  • University of Minnesota (US)
  • University of Wisconsin–Madison (US)
  • National Institutes of Health (US)
  • University of Arizona (US)
Corresponding author
  • Pampusch, Mary S.
  • Skinner, Pamela J.
ORCID
Venue
Molecular Therapy - Methods & Clinical Development
Publisher
Elsevier BV
Published
2020-03
Volume
16
Pages
1-10
ISSN
2329-0501 (ISSN-L)
DOI
10.1016/j.omtm.2019.09.007
PMC
PMC6816036
OpenAlex
W2978763546
Cited by
41
References
0
Citations by year
2026: 7 · 2025: 6 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 4 · 2020: 7
FWCI
1.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Therapy — Methods & Clinical Development (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • UA Campus Repository (The University of Arizona) (acceptedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
chimeric antigen receptor T cells, chimeric antigen receptor, T cell expansion, gene transduction, central memory T cells, rhesus monkeys, peripheral blood mononuclear cells, T cell therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review